Substituted pyridine and pyrimidine derivatives and their use in treating viral infections

US8697694B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• Southern Research Institute · US

Inventors

• Ashok Arasappan · Bound Brook, US
• F. George Njoroge · Hackettstown, US
• Cecil D. Kwong · Decatur, US
• Subramaniam Ananthan · Birmingham, US
• Frank Bennett · Piscataway, US
• Jeremy Clark · Birmingham, US
• Hollis S. Kezar, III · Hoover, US
• Vinay M. Girijavallabhan · Woburn, US
• Yuhua Huang · Westfield, US
• Regina Huelgas · New York, US
• Joseph A. Maddry · Birmingham, US
• John J. Piwinski · Lebanon, US
• Robert C. Reynolds · Birmingham, US
• Abhijit Roychowdhury · Birmingham, US
• Anita T. Fowler · Irondale, US
• Feng Geng · Hamburg, DE
• John A. Secrist, III · Birmingham, US
• Neng-Yang Shih · Lexington, US
• Vishal Verma · San Francisco, US
• Francisco Velazquez · Clinton, US
• Srikanth Venkatraman · Fords, US

Key dates

• Filing date: Aug 19, 2009
• Grant date: Apr 15, 2014
• Expiry date: May 1, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I): and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R1, X, Y, Z, R2, R3, R4, R5, R6, R7, R8, R9, R18, R19 and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing diseases or disorders such as viral infections and virus-related disorders.